Optic Neuritis, Optic; Neuritis, With Demyelination
Conditions
Keywords
Acute Optic Neuritis (AON), Demyelination, Optic Neuritis
Brief summary
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of BN201 in healthy subjects. This is a phase I, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of BN201 in healthy subjects following single ascending doses and two cohorts of multiple doses. The study will be conducted in two parts (Part A and Part B). Part A (up to 8 single ascending doses (SD)) will be conducted in 32 subjects (4 interlocking cohorts of 8 subjects). Part B (up to 2 multiple ascending doses (MD)) will be conducted in 16 subjects (2 cohorts of 8 subjects). Subjects in Part A will undergo a screening period (Day -28 to Day -2), two in-patient treatment periods compromising 3 overnight stays (from Day -1 to Day 3) with a wash out period of at least 14 days between dose administrations and a follow up visit 12 to 16 days following administration of IMP. Subjects in Part B will undergo a screening period (Day -28 to Day -2), an in-patient treatment period compromising 7 overnight stays (from Day -1 to Day 7) and a follow up visit 12 to 16 days following final administration of Investigational Medicinal Product (IMP).
Detailed description
Screening (Days -28 to -2) Screening assessments will be performed within 28 days of the first dose to ensure the eligibility of participants. Assessments will include medical history, demographics, concomitant medication check, physical examination, body weight, height, BMI, HIV, Hepatitis B and Hepatitis C screen, drugs of abuse and alcohol screen, routine laboratory assessments (biochemistry, haematology and urinalysis), 12-lead ECG, EEG monitoring, brain MRI scan, vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature. Female participants will also be screened for pregnancy and hormone status. A C-SSRS questionnaire will also be performed at screening for Part B only. Treatment Period Part A: Up to four cohorts ((SD1), (SD2), (SD3), (SD4)) of eight subjects will be randomly assigned to receive either two single intravenous doses of BN201, two single intravenous doses of placebo or one single intravenous dose of BN201 and placebo (per treatment period) over two treatment periods (Period 1 and Period 2). Within each cohort, 6 subjects will receive BN201 and 2 subjects will receive placebo. Two dose leader subjects will be dosed on the same day, at least 48 h before the remaining subjects in the cohort. Of these two subjects, one will be dosed with BN201 and the other with placebo. The Chief Investigator (or delegate) must confirm it is safe to continue with the dosing of the remainder of the cohort following review of appropriate safety data. The remaining 6 subjects of the cohort (five randomised to active and one to placebo) will then be dosed. Subjects will be admitted to the clinical unit in the morning of Day -1 and will remain in the unit until the 48 h post dose scheduled assessments and procedures have been performed (Day 3). On Day -1 of each Treatment Period subjects' eligibility will be re-assessed and blood and urine samples will be collected for laboratory safety tests (including drugs of abuse and alcohol screen, biochemistry, haematology, urinalysis and serum pregnancy test). A 12-lead ECG, vital signs (supine systolic and diastolic blood pressure, pulse), body temperature, adverse event and concomitant medication checks will be performed. The intravenous dose of BN201 or placebo will be based on body weight measured on Day -1. An evening snack will be consumed at least 10 hours (h) before (each) dose administration. After an overnight fast of at least 10 h, dose administration will occur on the morning of Day 1 between 08:00 and 11:00 whilst subjects are in a semi supine position. The subjects will remain in this position until 2 h post-infusion, however other positions are temporarily allowed for scheduled assessment requirements. Fasting will continue until 4 h after start of infusion; a standardised meal will then be administered. Subjects will be discharged from the clinical unit on Day 3 (48 h post-dose) providing there are no ongoing safety concerns. There will be a wash out period of at least 14 days between dose administrations prior to subjects returning for their treatment 2 scheduled assessments and procedures. The following assessments will be made during treatment Period 1 and Period 2: * Safety assessments: Adverse event (AEs) and concomitant medication check, physical examination, laboratory safety assessments (drugs of abuse and alcohol screen, biochemistry, haematology, urinalysis and serum pregnancy test), 12-lead ECG, telemetry, Holter monitoring, EEG monitoring, vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature, infusion site reaction assessment. * Pharmacokinetics (PK) assessments: Blood sample collection for measurement of BN201 in plasma. * Pharmacodynamics (PD) assessments: Blood sample collection for measurement of phosphorylation of N-myc downstream-regulated gene 1 (NDGR1) in peripheral blood mononuclear cells (PBMCs). * Pharmacogenomic assessments: Blood sample will be collected for potential genotyping of deoxyribonucleic acid (DNA) sequence variants to explore potential relationships with PK/PD and or tolerability. A follow-up visit (including a brain MRI scan) will be conducted 12 to 16 days following each administration of IMP. If all follow-up assessments are satisfactory to the Investigator following Treatment Period 2 the subject will be discharged from the study. If any AEs are ongoing, or any assessments not satisfactory subjects may be recalled to the unit for follow-up assessments until the Investigator is satisfied the subject may be discharged from the study. Subjects will be advised to return or contact the unit at any time if they may be experiencing any adverse effects. Enrolment of the subsequent cohort will only proceed, if blinded PK and safety data from the previous cohort has been reviewed by the Sponsor and Chief Investigator and is found to be satisfactory. Part B: Two cohorts (MD1, MD2) of eight subjects will be randomly assigned to receive either multiple intravenous doses of BN201 or multiple intravenous doses of placebo once daily for five consecutive days (Day 1 to Day 5). Within each cohort, 6 subjects will receive BN201 and 2 subjects will receive placebo. Two dose leader subjects will be dosed on the same day, at least 48 h before the remaining subjects in the cohort. Of these two subjects, one will be dosed with BN201 and the other with placebo. The Chief Investigator (or delegate) must confirm it is safe to continue with the dosing of the remainder of the cohort following review of appropriate safety data. The remaining 6 subjects of the cohort (five randomised to active and one to placebo) will then be dosed. The dose levels to be administered will be based on the safety, tolerability and PK results of Part A. Cohort MD1 can only be started if a higher dose level in the SAD part was well tolerated and that simulated PK modelling for multiple dose administration based on PK data from single doses do not suggest that the Cmax threshold of 13.3 μg/mL will be exceeded. Enrolment of MD2 will only proceed if blinded PK and safety data from subjects in MD1 has been reviewed by the Sponsor and Chief Investigator and is found to be satisfactory. A lower dose may be chosen if deemed appropriate following review of PK and safety data from Part A. Subjects will be admitted to the clinical unit in the morning of Day -1 and will remain in the unit until the scheduled assessments and procedures have been performed on Day 7, 48 h post-last dose. On Day -1 subjects' eligibility will be re-assessed and blood and urine samples will be collected for laboratory safety tests (including drugs of abuse and alcohol screen, biochemistry, haematology, urinalysis and serum pregnancy test). A 12-lead ECG, vital signs (supine systolic and diastolic blood pressure, pulse), body temperature, quantitative sensory testing (QST) and visual analogue scale (VAS) and adverse event and concomitant medication checks will be performed. The intravenous dose of BN201 or placebo will be based on body weight measured on Day -1. An evening snack will be consumed at least 10 h before (each) dose administration. After an overnight fast of at least 10 h, dose administration will occur on the mornings of Day 1 to Day 5 between 08:00 and 11:00 whilst subjects are in a semi supine position. The subjects will remain in this position until 2 h post-infusion, however other positions are temporarily allowed for scheduled assessment requirements. Fasting will continue until 4 h after start of infusion; a standardised meal will then be administered. Subjects will be discharged from the clinical unit on Day 7 providing there are no ongoing safety concerns. The following assessments will be made during Day -1 to Day 7: * Safety assessments: Adverse event (AEs) and concomitant medication check, physical examination, laboratory safety assessments (drugs of abuse and alcohol screen, biochemistry, haematology and urinalysis and serum pregnancy test), 12-lead ECG, telemetry, Holter monitoring, EEG monitoring\*, vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature, infusion site reaction assessment, C-SSRS questionnaire, QST and VAS. * PK assessments: Blood sample collection for measurement of BN201 in plasma. * PD assessments: Blood sample collection for measurement of phosphorylation of N-myc downstream-regulated gene 1 (NDGR1) in peripheral blood mononuclear cells (PBMCs). * Pharmacogenomic assessments: Blood sample will be collected for potential genotyping of deoxyribonucleic acid (DNA) sequence variants to explore potential relationships with PK/PD and or tolerability. * EEG monitoring only performed for Part B Cohort 2 if indicated from results from Part B Cohort 1 A follow-up visit (including a brain MRI scan) will be conducted 12 to 16 days following the subjects' final administration of IMP. If all follow up assessments are satisfactory to the Investigator, the subject will be discharged from the study. If any AEs are ongoing, or any assessments not satisfactory subjects may be recalled to the unit for follow-up assessments until the Investigator is satisfied the subject may be discharged from the study. Subjects will be advised to return or contact the unit at any time if they may be experiencing any adverse effects.
Interventions
DRUGComparison of BN201 treatment with Placebo
Single Dose or Multiple Dose of BN201 IV administration
Sponsors
Simbec Research
Accure Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
To be confirmed at screening: 1. Healthy male and female subjects between 18 and 55 years of age. 2. \*Healthy subjects as determined by past medical history and as judged by the PI (including no significant infection in the last 3 months before trial enrolment). 3. \*Female subject of non-child bearing potential with negative pregnancy test at screening and each admission to the clinical unit. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor. 4. \*Female subjects of child bearing potential must be non-pregnant and non-lactating with negative pregnancy test at screening and each admission to the clinical unit. 5. \*Female subjects of child bearing potential and male subjects with female partners of child bearing potential must take one highly effective contraceptive precaution in addition to one acceptable contraceptive precaution (i.e., barrier precaution) from first dose until 3 months after last dose of IMP (as detailed in Section 9.4.1). 6. \*Male subject willing to use an effective method of contraception or 2 effective methods of contraception, i.e., highly effective method of contraception + condom, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of IMP. 7. \*Subject with a body weight of ≥ 50.0 kg and ≤100 kg and have a body mass index (BMI) of 18-32 kg/m2. BMI = body weight (kg) / \[height (m)\]2. 8. \*Subject with no clinically significant history of previous allergy / sensitivity to BN201 or any of the excipients contained within the IMP. 9. \*Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 28 days before the first dose of IMP. 10. \*Subject with a negative urinary drugs of abuse screen, determined within 28 days before the first dose of IMP (N.B. a positive alcohol result may be repeated at Investigator's discretion). 11. Subject with negative human immunodeficiency virus (HIV) and hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV) results. 12. \*Subject with no clinically significant abnormalities in 12-lead electrocardiogram ((QTcF ≤ 430 ms) and (PR 120 - 200 ms)) determined within 28 days before first dose of IMP. 13. Subjects with no clinically significant abnormalities in electroencephalogram (EEG) determined within 28 days before first dose of IMP. 14. \*Subject with no clinically significant abnormalities in vital signs (supine systolic and diastolic blood pressure, pulse) and body temperature determined within 28 days before first dose of IMP. 15. Subject must be available to complete the study (including all follow up visits). 16. Subject must satisfy the investigator / designee about their fitness to participate in the study. 17. Subject must be willing and able to sign the written informed consent to participate in the study. 18. Subjects must not donate sperm for the first dose and for at least 3 months after the last dose of IMP. 19. Subject with no clinically significant abnormalities in brain MRI scan determined within 28 days before first dose of IMP. To be re-confirmed on Day -1 / prior to dosing: 1. Subject continues to meet all screening inclusion criteria indicated with \* (BMI will only apply to screening). 2. Subject with a negative urinary drugs of abuse screen (including alcohol) prior to dosing. 3. Female subject with negative pregnancy test.
Exclusion criteria
To be confirmed at screening: 1. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of IMP, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety. 2. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction. 3. A clinically significant history of drug or alcohol abuse. 4. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to dosing with the study medication or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums). 5. Inability to communicate well with Investigators (i.e., language problem, poor mental development or impaired cerebral function). 6. Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the 30 days before the first dose of IMP. (Washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study). 7. Donation of 450 mL or more blood within the 3 months before the first dose of IMP. To be re-confirmed at Day -1 / prior to dosing: 1. Development of any
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety: Physical Examination for musculoskeletal | Up to 17 days | Examination of musculoskeletal aspects |
| Safety: Holter Monitoring | Up to 5 days | Cardiac rhythm measure |
| Safety: Electroencephalography (EEG) Recording | Up to 5 days | Electrical activity measure |
| Safety: Concomitant Medication Recording | Up to 17 days | All prior and concomitant medications taken record |
| Safety: Physical Examination for nose | Up to 17 days | Examination of nose |
| Safety: Physical Examination for throat | Up to 17 days | Examination of throat |
| Safety: Physical Examination for eye | Up to 17 days | Examination of ophthalmological aspects |
| Safety: Physical Examination for skin | Up to 17 days | Examination of dermatological aspects |
| Safety: Physical Examination for cardiovascular | Up to 17 days | Examination of cardiovascular aspects |
| Safety: Physical Examination for Respiratory | Up to 17 days | Examination of respiratory aspects |
| Safety: Physical Examination for gastrointestinal | Up to 17 days | Examination of gastrointestinal aspects |
| Safety: Physical Examination for Central Nervous System | Up to 17 days | Examination of central nervous system |
| Safety: Physical Examination for Lymph Nodes | Up to 17 days | Examination of lymph nodes |
| Safety: Routine Laboratory Safety Screen on Biochemistry | Up to 17 days | Analysis for Biochemistry |
| Safety: Routine Laboratory Safety Screen on Urinary Potassium | Up to 17 days | Analysis for Urinary Potassium |
| Safety: Vital signs Measures on Systolic blood pressure | Up to 17 days | Check of Systolic blood pressure |
| Safety: Vital signs Measures on Diastolic blood pressure | Up to 17 days | Check of Diastolic blood pressure |
| Safety: Adverse Events (AEs) and serious adverse events (SAEs) Reporting | Up to 17 days | All AEs will be recorded, whether considered minor or serious, drug-related or not. |
| Safety: Routine Laboratory Safety Screen on Haematology | Up to 17 days | Analysis for Haematology |
| Safety: Routine Laboratory Safety Screen on Urinary Sodium | Up to 17 days | Analysis for Urinary Sodium |
| Safety: Vital signs Measures on oral body temperature | Up to 17 days | Check of oral body temperature |
| Safety: Vital signs Measures on Pulse rate | Up to 17 days | Check of pulse rate |
| Magnetic resonance imaging (MRI) brain scan | Up to 17 days | Non-contrast MRI brain scans |
| Safety: Suicide Risk assessement | Up to 17 days | Assessment of Suicide-related thoughts and behaviours using Columbia-Suicide Severity Rating Scale (C-SSRS) Questionnaire |
| Safety: Physical Examination for ear | Up to 17 days | Examination of ear |
| Safety: 12-lead Electrocardiography (ECG) Recording | Up to 17 days | Performance of ECGs in the supine position |
| Safety: Telemetry Monitoring | Up to 5 days | Cardiac rhythm measure |
| Safety: Pain report | Day 5 | Spontaneous (neuropathic) pain report using Visual Analogue Scale (VAS) tool |
| Safety: Quantitative Sensory Testing (QST) | Day 5 | Evaluation of increase in mechano-sensitivity |
| Safety: Infusion Site Reaction Assessment | Up to 17 days | Assessment of Infusion Site Reaction |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic Parameter: Vz measurement | From pre-dose to 24 hours post-start-infusion | Volume of distribution |
| Pharmacokinetic Parameter: Cmax measurement | From pre-dose to 24 hours post-start-infusion | Maximum concentration measurement in plasma |
| Pharmacokinetic Parameter: Tm concentration measurement | From pre-dose to 24 hours post-start-infusion | Time to maximum observed concentration in plasma |
| Pharmacokinetic Parameter: kel measurement | From pre-dose to 24 hours post-start-infusion | Elimination rate constant in plasma |
| Pharmacokinetic Parameter: t1/2 measurement | From pre-dose to 24 hours post-start-infusion | Terminal elimination half-life in plasma |
| Pharmacokinetic Parameter: AUC 0-τ measurement | From pre-dose to 24 hours post-start-infusion | Area under the concentration-time curve (AUC) from 0 to τ, where τ is the dosing interval (0 - 24 h) in plasma |
| Pharmacokinetic Parameter: AUC 0-t measurement | From pre-dose to 24 hours post-start-infusion | Area under the concentration-time curve (AUC) from the time of dosing to the time of the last measurable concentration in plasma |
| Pharmacokinetic Parameter: AUC 0-inf measurement | From pre-dose to 24 hours post-start-infusion | AUC extrapolated to infinity |
| Pharmacokinetic Parameter: AUC % measurement | From pre-dose to 24 hours post-start-infusion | extrapolated Residual area |
| Pharmacokinetic Parameter: Clearance (CL) measurement | From pre-dose to 24 hours post-start-infusion | Clearance |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamic Parameter: Phosphorylation of N-myc downstream regulated 1 (NDRG1) measurement | Up to 2 hours post start infusion | NDRG1 phosphorylation in PBMCs |
| Pharmacogenomics Parameter: Sequencing of DNA in blood samples | Day 1 | Potential genotyping of deoxyribonucleic acid (DNA) sequence variants in blood sample |
Countries
United Kingdom
Outcome results
None listed